+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peptide Therapeutics: Contract API Manufacturing Market, 2020 - 2030

  • ID: 5025048
  • Report
  • March 2020
  • Region: Global
  • 285 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AAPPTec
  • APL
  • Cara Therapeutics
  • Europe Pharmaceuticals
  • Lyotex
  • Pfanstiehl
  • MORE

Overview

Since the establishment of the therapeutic relevance of insulin in the early 1920s, peptide therapeutics have come a long way. Presently, there are over 60 peptide-based drugs available in the market. Specifically, these products represent one of the earliest classes of biologics and have, so far, demonstrated significant potential in the treatment of a variety of metabolic and oncological disorders. Examples of popular, marketed therapeutic peptides include Victoza®, LUPRON DEPOT®, Zoladex®, Sandostatin® and Somatuline®. Further, according to experts, more than 600 pharmacological leads based on peptides are currently being investigated across various phases of development. Owing to their proven pharmacological value and favorable safety profiles, the demand for peptide drugs is on the rise. As a result, there is increasing interest in manufacturing solutions for large quantities of such molecules, often requiring complex manipulations of long macromolecular structures, chemical modifications and thorough purification, for both clinical and basic research applications.

Although a lot has been achieved in terms of improvements in peptide synthesis and purification methods, there are certain challenges, especially those related to large-scale manufacturing capabilities, which continue to plague drug developers in this domain. Additionally, there are certain technical complications related to the synthesis of complex, long chain macromolecules, which are known to compromise both product yield and purity. In order to optimize production processes and associated expenses, leverage superior expertise and infrastructure, and expedite time to market, many innovator companies have demonstrated the preference to work with specialty service providers. Presently, there are a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that offer elaborate portfolios of services focused on peptide design, manufacturing and purification. Given the historical and prevalent trends in demand for peptide synthesis and purification services, several CMOs/CDMOs are actively expanding their capabilities and capacity to ensure consistent supply. We are led to believe that sponsor companies are likely to continue relying on contract manufacturing service providers over the coming decade.
Scope of the Report

The “Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract services for manufacturing of peptides, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used, type of peptide modification services offered, peptide purification technology used, and regulatory accreditations/certifications.   
  • An analysis on the recent developments in the industry, highlighting collaborations, facility expansions, and upcoming peptide synthesis technologies within this domain.
  • Informed estimates of the annual commercial and clinical demand for manufacturing peptides for therapeutic use, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A clinical trial analysis of completed, and active studies related to peptide therapeutics that are have been/being/likely to be conducted across various geographies, based on the trial registration year, trial phase, trial recruitment status, therapeutic areas type of sponsor/collaborator, geography and number of patients enrolled.
  • An estimate of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available peptide production capacity across companies of different sizes (small, mid-sized, large and very large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific).
  • A discussion on regulatory guidelines related to peptide manufacturing, highlighting key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.
  • Elaborate profiles of the key players that offer contract manufacturing services across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.  
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptide contract manufacturing market. Based on multiple parameters, such as projected growth of overall peptide-based products market, cost of goods sold and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] distribution scale of operation (preclinical/clinical and commercial) [B] type of synthesis method used [C] end user (small, mid-sized and large/very large), and [D] key geographical regions (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AAPPTec
  • APL
  • Cara Therapeutics
  • Europe Pharmaceuticals
  • Lyotex
  • Pfanstiehl
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Peptides
3.2.1. Structure of Peptides
3.2.2. Major Classes of Peptides
3.2.3. Synthesis of Peptides
3.2.4. Modification of Peptides
3.2.4.1. N-terminal Modification
3.2.4.2. Internal Modification
3.2.4.3. C-terminal Modification
3.2.4.4. Other Modifications
3.2.5. Purification of Peptides
3.2.6. Applications of Peptides
3.3. Overview of Contract Manufacturing
3.3.1. Need for Outsourcing in the Peptide Industry
3.3.2. Key Considerations for Selecting a CMO Partner
3.3.3. Advantages of Outsourcing Manufacturing Services
3.3.4. Risks and Challenges Associated with Outsourcing Peptide Manufacturing Services
3.4. Future Perspectives

4. REGULATORY LANDSCAPE
4.1. Chapter Overview
4.2. Regulatory Scenario in North America
4.2.1. The US Scenario
4.2.1.1. Overview
4.2.1.2. General Guidelines
4.3. Regulatory Scenario in Europe
4.3.1. The European Scenario
4.3.1.1. Overview
4.3.1.2. General Guidelines
4.4. Regulatory Scenario in Asia Pacific
4.4.1. Overview
4.4.2. Australian Scenario
4.4.2.1. General Guidelines
4.4.3. Chinese Scenario
4.4.3.1. General Guidelines
4.4.4. Indian Scenario
4.4.4.1. General Guidelines
4.4.5. Japanese Scenario
4.4.5.1. General Guidelines
4.4.6. South Korean Scenario
4.4.6.1. General Guidelines
4.5. Challenges Associated with Peptide Manufacturing

5. COMPETITIVE LANDSCAPE
5.1 Chapter Overview
5.2 Contract Peptide API Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Peptide Synthesis Method Used
5.2.7. Analysis by Peptide Modification Services Offered
5.2.8. Analysis by Purification Technology Used
5.2.9. Analysis by Regulatory Accreditations / Certifications

6. COMPANY PROFILES
6.1 Chapter Overview
6.2. Contract Peptide API Manufacturers based in North America
6.2.1. AmbioPharm
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Facilities and Capabilities
6.2.1.4. Recent Development and Future Outlook
6.2.2. CPC Scientific
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Facilities and Capabilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Creative Peptides
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Facilities and Capabilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4. CSBio
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Facilities and Capabilities
6.2.4.4. Recent Developments and Future Outlook
6.3. Contract Peptide API Manufacturers based in Europe
6.3.1. Bachem
6.3.1.1. Recent Developments and Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Facilities and Capabilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2. BCN Peptide
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Facilities and Capabilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Corden Pharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Facilities and Capabilities
6.3.3.4. Recent Developments and Future Outlook
6.3.4. PolyPeptide
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Manufacturing Facilities and Capabilities
6.3.4.4. Recent Developments and Future Outlook
6.3.5. Senn Chemicals
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Manufacturing Facilities and Capabilities
6.3.5.4. Recent Developments and Future Outlook
6.4. Contract Peptide API Manufacturers based in Asia Pacific
6.4.1. Auspep
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Facilities and Capabilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Chinese Peptide
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Facilities and Capabilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Hybio Pharmaceutical
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Facilities and Capabilities
6.4.3.4. Recent Developments and Future Outlook
6.4.4. Peptide Institute
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Manufacturing Facilities and Capabilities
6.4.4.4. Recent Developments and Future Outlook
6.4.5. ScinoPharm
6.4.5.1. Company Overview
6.4.5.2. Service Portfolio
6.4.5.3. Manufacturing Facilities and Capabilities
6.4.5.4. Recent Developments and Future Outlook

7. RECENT DEVELOPMENTS
7.1. Chapter Overview
7.2. Partnerships Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation (Deal Specific)
7.3.4. Analysis by Region
7.4. Expansion Models
7.5. List of Expansions
7.5.1. Analysis by Year of Expansion
7.5.2. Analysis by Type of Expansion
7.5.3. Analysis by Location of Expansion Project
7.6. Emerging Peptide Synthesis Technologies

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3 Peptide Therapeutics: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Trial Recruitment Status
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Sponsor / Collaborator
8.3.6. Analysis by Geography
8.3.7. Geographical Analysis by Trial Recruitment Status
8.3.8. Geographical Analysis by Trial Phase
8.4. Peptide Therapeutics: Analysis of Enrolled Patient Population
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Recruitment Status and Therapeutic Area
8.4.3. Analysis by Trial Location
8.4.4. Analysis by Trial Recruitment Status and Location
8.4.5. Analysis of Active Trials by Trial Phase and Location

9. REGIONAL CAPABILITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Regional Capability Analysis: Contract Peptide API Manufacturers in North America
9.4. Regional Capability Analysis: Contract Peptide API Manufacturers in Europe
9.5. Regional Capability Analysis: Contract Peptide API Manufacturing in Asia Pacific and Rest of the World

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodologies
10.3. Peptide API Manufacturing: Overall Annual Demand
10.3.1. Analysis by Scale of Operation
10.3.2. Analysis by Geography

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodologies
11.3. Peptide API Manufacturing: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1. Chapter Overview
12.2. Assumptions and Key Parameters
12.3. Peptide Therapeutics Contract API Manufacturing: Make versus Buy Decision Making
12.4. Conclusion

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology
13.3. Overall Contract Peptide API Manufacturing Market, 2020-2030
13.4. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.5. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Peptide Synthesis Method Used
13.6. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by End User
13.7. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions
13.7.1. Contract Peptide API Manufacturing Market in North America, 2020-2030
13.7.1.1. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.7.1.2. Contract Peptide API Manufacturing Market in North America,2020-2030: Share of Mid-sized Companies
13.7.1.3. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.7.1.4. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.1.5. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.7.1.6. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods
13.7.1.7. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030
13.7.2.1. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.7.2.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.7.2.4. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.2.5. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.7.2.6. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods
13.7.2.7. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods
13.7.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030
13.7.3.1. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.2. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.4. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.5. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Scale Operations
13.7.3.6. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.7. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remark

15. CONCLUSION
15.1. Chapter Overview
15.2. Key Takeaways

16. SURVEY INSIGHTS

17. APPENDIX 1: TABULATED DATA

List Of Figures
Figure 3.1. Primary Structure of Peptides
Figure 3.2. Secondary Structure of Peptides
Figure 3.3. Tertiary Structure of Peptides
Figure 3.4. Quaternary Structure of Peptides
Figure 3.5. Peptide Synthesis Methods
Figure 3.6. Different Type of Peptide Modifications
Figure 3.7. Type of Third-Party Service Providers
Figure 4.1. Regulatory Landscape: Peptide Classification in the US
Figure 5.1. Contract Peptide API Manufacturers: Distribution by Year of Establishment
Figure 5.2. Contract Peptide API Manufacturers: Distribution by Company Size
Figure 5.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Figure 5.4. Contract Peptide API Manufacturers: Distribution by Location of Headquarters
Figure 5.5. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.6. Contract Peptide API Manufacturers: Distribution by Peptide Synthesis Method Used
Figure 5.7. Contract Peptide API Manufacturers: Distribution by Peptide Modification Services Offered
Figure 5.8. Contract Peptide API Manufacturers: Distribution by Purification Technology Used
Figure 5.9. Contract Peptide API Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 6.1. AmbioPharm: Service Portfolio
Figure 6.2. CPC Scientific: Service Portfolio
Figure 6.3. Creative Peptides: Service Portfolio
Figure 6.4. CSBio: Service Portfolio
Figure 6.5. Bachem: Service Portfolio
Figure 6.6. BCN Peptide: Service Portfolio
Figure 6.7. Corden Pharma: Service Portfolio
Figure 6.8. PolyPeptide: Service Portfolio
Figure 6.9. Senn Chemical: Service Portfolio
Figure 6.10. Auspep: Service Portfolio
Figure 6.11. Chinese Peptide: Service Portfolio
Figure 6.12. Hybio Pharmaceuticals: Service Portfolio
Figure 6.13. Peptide Institute: Service Portfolio
Figure 6.14. ScinoPharm: Service Portfolio
Figure 7.1. Recent Partnerships: Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership
Figure 7.3. Recent Partnerships: Distribution by Scale of Operations
Figure 7.4. Recent Partnerships: Continent-Wise Distribution
Figure 7.5. Recent Partnerships: Country-Wise Distribution
Figure 7.6. Recent Expansions: Distribution by Year of Expansion
Figure 7.7. Recent Expansions: Distribution by Type of Expansion
Figure 7.8. Recent Expansions: Distribution by Location of Expansion Project
Figure 8.1. Clinical Trial Analysis: Distribution by Trial Registration Year, 2010-2019
Figure 8.2. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 8.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 8.5. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.6. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.7. Clinical Trial Analysis: Distribution by Geography
Figure 8.8. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 8.9. Clinical Trial Analysis: Geographical Distribution of Active Trials by Trial Phase
Figure 8.10. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 8.11. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Therapeutic Area
Figure 8.12. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Location
Figure 8.13. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Location
Figure 8.14. Clinical Trial Analysis: Distribution of Enrolled Patient Population of Active Trials by Trial Phase and Location
Figure 9.1. Regional Capability Analysis: North America
Figure 9.2. Regional Capability Analysis: Europe
Figure 9.3. Regional Capability Analysis: Asia Pacific and Rest of the World
Figure 10.1. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Figure 10.2. Demand Analysis: Annual Demand for Clinical Scale of Operation
Figure 10.3. Demand Analysis: Annual Demand for Commercial Scale of Operation
Figure 10.4. Demand Analysis: Annual Demand in North America
Figure 10.5. Demand Analysis: Annual Demand in Europe
Figure 10.6. Demand Analysis: Annual Demand in Asia Pacific
Figure 11.1. Contract Peptide API Manufacturers: Installed Global Capacity
Figure 11.2. Contract Peptide API Manufacturers: Distribution by Company Size
Figure 11.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Figure 11.4. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facility
Figure 12.1. Make versus Buy Decision Making Framework
Figure 12.2. Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 13.1. Overall Contract Peptide API Manufacturing Market, 2020-2030 (USD Million)
Figure 13.2. Contract Peptide API Manufacturing Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 13.3. Contract Peptide API Manufacturing Market: Distribution by Peptide Synthesis Methods Used, 2020-2030 (USD Million)
Figure 13.4. Contract Peptide API Manufacturing Market: Distribution by Type of End User, 2020-2030 (USD Million)
Figure 13.5. Contract Peptide API Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
Figure 13.5. Contract Peptide API Manufacturing Market in North America, 2020-2030 (USD Million)
Figure 13.6. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Million)
Figure 13.7. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.8. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.9. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.10. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.11. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.12. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 13.13. Contract Peptide API Manufacturing Market in Europe, 2020-2030 (USD Million)
Figure 13.14. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Million)
Figure 13.15. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.16. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.17. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.18. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.19. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.20. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 13.21. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030 (USD Million)
Figure 13.22. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Million)
Figure 13.23. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.24. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.25. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.26. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.27. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.28. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 14.1. Contract Peptide API Manufacturing: SWOT Analysis
Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables
Table 3.1. Comparison of Various Peptide Synthesis Methods
Table 3.2. Chromatographic Techniques
Table 5.1. List of Contract Peptide API Manufacturers
Table 5.2. Contract Peptide API Manufacturers: Information on Scale of Operation
Table 5.3. Contract Peptide API Manufacturers: Information on Peptide Synthesis Methods Used
Table 5.3. Contract Peptide API Manufacturers: Information on Peptide Modification Services Offered
Table 5.4. Contract Peptide API Manufacturers: Information on Purification Technology Used
Table 5.5. Contract Peptide API Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1. AmbioPharm: Company Overview
Table 6.2. AmbioPharm: Overview of Manufacturing Capabilities
Table 6.3. AmbioPharm: Recent developments and Future Outlook
Table 6.4. CPC Scientific: Company Overview
Table 6.5. CPC Scientific: Overview of Manufacturing Capabilities
Table 6.6. CPC Scientific: Recent developments and Future Outlook
Table 6.7. Creative Peptides: Company Overview
Table 6.8. Creative Peptides: Overview of Manufacturing Capabilities
Table 6.9. Creative Peptides: Recent developments and Future Outlook
Table 6.10. CSBio: Company Overview
Table 6.11. CSBio: Overview of Manufacturing Capabilities
Table 6.12. CSBio: Recent developments and Future Outlook
Table 6.13. Bachem: Company Overview
Table 6.14. Bachem: Overview of Manufacturing Capabilities
Table 6.15. Bachem: Recent developments and Future Outlook
Table 6.16. BCN Peptide: Company Overview
Table 6.17. BCN Peptide: Overview of Manufacturing Capabilities
Table 6.18. BCN Peptide: Recent developments and Future Outlook
Table 6.19. Corden Pharma: Company Overview
Table 6.20. Corden Pharma: Overview of Manufacturing Capabilities
Table 6.21. Corden Pharma: Recent developments and Future Outlook
Table 6.22. PolyPeptide: Company Overview
Table 6.23. PolyPeptide: Overview of Manufacturing Capabilities
Table 6.24. PolyPeptide: Recent developments and Future Outlook
Table 6.25. Senn Chemicals: Company Overview
Table 6.26. Senn Chemicals: Overview of Manufacturing Capabilities
Table 6.27. Senn Chemical: Recent developments and Future Outlook
Table 6.28. Auspep: Company Overview
Table 6.29. Auspep: Overview of Manufacturing Capabilities
Table 6.30. Auspep: Recent developments and Future Outlook
Table 6.31. Chinese Peptide: Company Overview
Table 6.32. Chinese Peptide: Overview of Manufacturing Capabilities
Table 6.33. Chinese Peptide: Recent developments and Future Outlook
Table 6.34. Hybio Pharmaceuticals: Company Overview
Table 6.35. Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 6.36. Hybio Pharmaceuticals: Recent developments and Future Outlook
Table 6.37. Peptide Institute: Company Overview
Table 6.38. Peptide Institute: Overview of Manufacturing Capabilities
Table 6.39. Peptide Institute: Recent developments and Future Outlook
Table 6.40. ScinoPharm: Company Overview
Table 6.41. ScinoPharm: Overview of Manufacturing Capabilities
Table 6.42. ScinoPharm: Recent developments and Future Outlook
Table 7.1. Contract Peptide API Manufacturers: List of Partnerships, 2014-2020
Table 7.2. Contract Peptide API Manufacturers: List of Recent Expansions, 2014-2020
Table 7.3. Contract Peptide API Manufacturers: List of Emerging Peptide Synthesis / Manufacturing Technologies
Table 12.1. Parameters to Assess Complexity of Outsourcing Manufacturing Operations
Table 12.2. Contract Peptide API Manufacturing: Make versus Buy Decision Making
Table 17.1. Contract Peptide API Manufacturers: Distribution by Year of Establishment
Table 17.2. Contract Peptide API Manufacturers: Distribution by Company Size
Table 17.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Table 17.4. Contract Peptide API Manufacturers: Distribution by Location of Headquarters
Table 17.5. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facilities
Table 17.6. Contract Peptide API Manufacturers: Distribution by Type of Peptide Synthesis Methods Used
Table 17.7. Contract Peptide API Manufacturers: Distribution by Type of Peptide Modification Services Offered
Table 17.8. Contract Peptide API Manufacturers: Distribution by Type of Purification Technology Used
Table 17.9. Contract Peptide API Manufacturers: Distribution by Regulatory Accreditations / Certifications
Table 17.10 Partnerships: Distribution by Year of Partnerships
Table 17.11. Partnerships: Distribution by Type of Partnerships
Table 17.12. Partnerships: Distribution by Scale of Operations
Table 17.13. Partnerships: Country-Wise Distribution
Table 17.14. Partnerships: Continent-Wise Distribution
Table 17.15. Recent Expansions: Distribution by Year of Expansion
Table 17.16. Recent Expansions: Distribution by Type of Expansion
Table 17.17. Recent Expansions: Distribution by Location of Expansion Project
Table 17.18. Clinical Trial Analysis: Distribution by Trial Registration Year, Since-2010
Table 17.19. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 17.20. Clinical Trial Analysis: Distribution by Trial Phase
Table 17.21. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 17.22. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.23. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24. Clinical Trial Analysis: Distribution by Geography
Table 17.25. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 17.26. Clinical Trial Analysis: Geographical Distribution of Active Trials by Trial Phase
Table 17.27. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 17.28. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 17.29. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area and Trial Recruitment Status
Table 17.30. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Recruitment Status
Table 17.31. Clinical Trial Analysis: Distribution of Enrolled Patient Population of Active Trials by Trial Phase and Location
Table 17.32. Regional Capability Analysis in North America
Table 17.33. Regional Capability Analysis in Europe
Table 17.34. Regional Capability Analysis in Asia Pacific
Table 17.35. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Table 17.36. Demand Analysis: Annual Demand for Clinical Scale of Operation
Table 17.37. Demand Analysis: Annual Demand for Commercial Scale of Operation
Table 17.38. Demand Analysis: Annual Demand in North America
Table 17.39. Demand Analysis: Annual Demand in Europe
Table 17.40. Demand Analysis: Annual Demand in Asia Pacific
Table 17.41. Contract Peptide API Manufacturers: Installed Global Capacity
Table 17.42. Contract Peptide API Manufacturers: Distribution by Company Size
Table 17.43. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Table 17.44. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facility
Table 17.45. Overall Contract API Peptide Manufacturing Market, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.46. Contract Peptide API Manufacturing Market: Distribution by Scale of Operation, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.47. Contract API Peptide Manufacturing Market: Distribution by Peptide Synthesis Methods Used, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.48. Contract API Peptide Manufacturing Market: Distribution by Type of End User, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.49. Contract Peptide API Manufacturing Market: Distribution by Key Geographic Regions, 2020-2030 (USD Million)
Table 17.50. Contract API Peptide Manufacturing Market in North America, 2020, 2025 and 2030 (USD Million)
Table 17.51. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.52. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.53. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.54. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.55. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.56. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods Used (USD Million)
Table 17.57. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Table 17.58. Contract API Peptide Manufacturing Market in Europe, 2020, 2025 and 2030 (USD Million)
Table 17.59. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.60. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.61. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.62. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.63. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.64. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Table 17.65. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Table 17.66. Contract API Peptide Manufacturing Market in Asia Pacific, 2020, 2025 and 2030 (USD Million)
Table 17.67. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.68. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.69. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.70. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.71. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.72. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Table 17.73. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)

Note: Product cover images may vary from those shown
  • AAPPTec
  • Abcepta
  • Abclonal
  • ABI Scientific
  • Abzena
  • ACES Pharma
  • Active Peptide
  • Activotec
  • Adar Biotech
  • Advanced ChemTech
  • Ajinomoto Bio-Pharma
  • Alpha Diagnostic
  • AltaBioscience
  • AmbioPharm
  • American Peptide
  • Amunix
  • AnaSpec
  • Antagene
  • APL
  • Arch Biopartners
  • AstraZeneca
  • Asymchem
  • Atlantic Peptides
  • Auspep
  • Austin Chemical
  • Baccinex
  • Bachem
  • BCN Peptides
  • Bio Basic
  • Biopeptek Pharmaceuticals
  • BioServUK
  • Bio-Synthesis
  • BioVectra
  • Burrard Pharmaceuticals
  • California Peptide Research
  • Cambridge Peptides
  • CanPeptide
  • Cara Therapeutics
  • CARBOGEN AMCIS
  • CASLO
  • CBL (Chemical and Biopharmaceutical Laboratories)
  • Celtek Peptides
  • ChemPartner
  • CHI Scientific
  • Chiasma
  • ChinaPeptides
  • Chinese Peptide
  • CordenPharma
  • Cosmo Bio
  • CPC Scientific
  • Creative Peptides
  • CSBio
  • Dalton Pharma
  • Dr. Reddy's Custom Pharma Services
  • Eli Lilly
  • Enteris BioPharma
  • EOC Pharma
  • Europe Pharmaceuticals
  • GenPro Biotech
  • GenScript
  • GL Biochem
  • GLyPharma Therapeutic
  • GP Pharm
  • Grey Matter Research Foundation
  • HAMLET Pharma
  • Hybio Pharmaceutical
  • i-DNA Biotechnology
  • IDP Pharma
  • Innovagen
  • Institute Of Biomolecules Max Mousseron
  • INTAVIS Bioanalytical Instruments
  • Iris Biotech
  • Jitsubo
  • Kaijie Peptide
  • KareBayTM Biochem
  • KeyBioscience
  • Kinexus
  • Lonza
  • Lyotex
  • Macrocyclics
  • Mimotopes
  • MuseChem
  • Neuland
  • New England Peptide
  • Novetide
  • NUMAFERM
  • Ontores
  • Oryn
  • PEPDesign
  • Pepscan
  • Peptide  International
  • Peptide 2.0
  • Peptide Institute
  • Peptide Protein Research
  • peptides&elephants
  • Peptron
  • Pfanstiehl
  • PolyPeptide
  • Primm Biotech
  • Priveel peptides
  • ProImmune
  • Promore Pharma
  • ProteoGenix
  • Provepharm
  • Quantum Hi-Tech
  • RS Synthesis
  • SBS Genetech
  • Scancell
  • ScinoPharm
  • Sekisui XenoTech
  • Selleck Chemicals
  • Senn Chemicals
  • Shenzhen JYMed Technology
  • STA Pharmaceutical
  • UNC Lineberger Comprehensive Cancer Center
  • United BioSystems
  • UPM Pharmaceuticals
  • Wilshire Technologies
  • Xaia Custom Peptides
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll